Legend Biotech Corporation
LEGN
$32.80
-$0.66-1.97%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 65.84% | 31.65% | 46.43% | 9.94% | -16.11% |
| Total Depreciation and Amortization | 16.35% | 10.21% | 9.87% | 13.08% | 16.58% |
| Total Amortization of Deferred Charges | -6.59% | -12.10% | -15.97% | -30.45% | -23.42% |
| Total Other Non-Cash Items | -105.96% | -47.23% | -84.27% | 111.69% | 345.56% |
| Change in Net Operating Assets | 128.21% | 1,307.33% | 103.23% | -60.72% | -138.10% |
| Cash from Operations | 63.38% | 54.63% | 60.23% | 8.89% | -95.39% |
| Capital Expenditure | 29.77% | 27.90% | 0.56% | -68.58% | 4.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -200.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -841.06% | -26.77% | -1,410.87% | -261.16% | 300.96% |
| Cash from Investing | -1,016.67% | -22.57% | -1,993.80% | -286.30% | 220.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -7.00% | 49.18% | 25.02% | -24.29% | -44.65% |
| Issuance of Common Stock | -98.78% | -98.78% | -99.40% | 109.33% | 108.96% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.28% | -99.12% | -99.69% | 110.00% | 109.40% |
| Foreign Exchange rate Adjustments | -405.72% | 187.40% | 120.44% | 155.25% | 127.17% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -301.55% | -434.49% | -220.92% | -15.85% | 406.40% |